



Published in final edited form as:

Support Care Cancer. 2014 May ; 22(5): 1161–1169. doi:10.1007/s00520-013-2068-0.

## Evaluation of Chemotherapy-Induced Peripheral Neuropathy using Current Perception Threshold and Clinical Evaluations

**Kathleen A. Griffith, PhD, MPH, CRNP\*<sup>#</sup>,**

Assistant Professor, Organizational Systems and Adult Health, University of Maryland. Baltimore, School of Nursing, 655 W. Lombard Street, 729B, Baltimore, MD 21201-1579, Phone: 410-706-1165, Fax: 410-706-5429

**Darren J. Couture, CDR, CRNA, PhD\*<sup>#</sup>,**

Assistant Professor/Clinical Research Director, Uniformed Services University of the Health Sciences, Naval Medical Center San Diego, CA, 34800 Bob Wilson Drive, San Diego, CA 92134, Phone: 619-532-8966, Fax: 619-532-8954

**Shijun Zhu, PhD,**

University of Maryland, Baltimore, School of Nursing, room 402K, 655 W. Lombard Street, Baltimore, MD 21201-1579, Phone: 410-706-2953, Fax: 410-706-3289

**Naimish Pandya, MD,**

Associate Medical Director, MedImmune, 35 West Watkins Mill Road, Gaithersburg, MD 20878, Phone: (301) 298-5450

**Mary E. Johantgen, PhD, RN,**

Associate Professor, Organizational Systems and Adult Health, University of Maryland. Baltimore, School of Nursing, 655 W. Lombard Street, room 475B, Baltimore, MD 21201-1579, Phone: 410-706-0520, Fax: 410-706-3289

**Guido Cavaletti, MD,**

Head, Experimental Neurology Unit, Dept. Surgery and Translational Medicine, University of Milano-Bicocca, via Cadore 48 - 20900 Monza (MB), Italy, Phone: + 39 02 6448 8039, Fax: + 39 02 6448 8250

**Joan M. Davenport, RN, PhD,**

Assistant Professor, University of Maryland School of Nursing Office 345 C, 655 W. Lombard Street, Baltimore, MD 21201, 410-706-3688, 410 706 0344 (fax)

**Lori J. Tanguay, MS, RN,**

University of Maryland Medical Center, Greenebaum Cancer Center, Stoler Pavilion, 22 S. Greene St., Baltimore, MD 21201, 410-328-1515, 410-328-9226 (fax)

**Amanda Choflet, MS, RN, OCN,**

Department of Radiation Oncology & Molecular Sciences, Johns Hopkins Medicine, 401 North Broadway, Suite 1440, Baltimore, MD 21231, Phone: 410.955.6980, Fax: 410.502.1780

**Todd Milliron, RN,**

University of Maryland Medical System, Marlene and Stewart Greenebaum Cancer Center, 22 S. Greene St., Baltimore, MD 21201, Phone 410-328-2059, Pager 410-389-2466

**Erica Glass, CRNP, MS, RN, BSN,**

<sup>#</sup>Co-corresponding authors: Kathleen A. Griffith: Griffith@son.umaryland.edu. Cynthia Renn, Renn@son.umaryland.edu.

<sup>\*</sup>Co-first authors

The views expressed are those of the authors and do not reflect the official policy or position of the Uniformed Services University of the Health Sciences, the Department of Defense, or the United States government.

St. Agnes Cancer Institute, 900 S. Caton Ave MS 235, Baltimore, MD 21229, Phone: 410-368-8777, Cell: 845-642-0573, Fax: 410-951-4046

**Nancy Gambill, MS, CRNP,**

Director, Oncology Nursing, University of Maryland Medical System, Marlene and Stewart Greenebaum Cancer Center, 22 S. Greene St., Baltimore, MD 21201, Phone: 410-328-1561, Fax: 410-328-3780

**Cynthia L. Renn, PhD, RN<sup>#</sup>, and**

Assistant Professor, Organizational Systems & Adult Health, University of Maryland, Baltimore, School of Nursing, Room 729A, Phone: 410-706-5736, Fax: 410-706-5429

**Susan G. Dorsey, PhD, RN, FAAN**

Associate Professor, University of Maryland Baltimore, School of Nursing, Suite 727, 655 W Lombard Street, Baltimore MD 21201, Phone: 410-706-7250, Fax: 410-706-5429

Kathleen A. Griffith: Griffith@son.umaryland.edu; Darren J. Couture: DJCouture1@mac.com; Shijun Zhu: Zhu@son.umaryland.edu; Naimish Pandya: PandyaN@MedImmune.com; Mary E. Johantgen: Johantgen@son.umaryland.edu; Guido Cavaletti: Guido.Cavaletti@unimib.it; Joan M. Davenport: davenport@son.umaryland.edu; Lori J. Tanguay: Ltanguay@umm.edu; Amanda Choflet: achofle1@jhmi.edu; Todd Milliron: tmilliron@umm.edu; Erica Glass: Erica.Glass@stagnes.org; Nancy Gambill: ngambill@umm.edu; Cynthia L. Renn: Renn@son.umaryland.edu; Susan G. Dorsey: sdorsey@son.umaryland.edu

## Abstract

**Purpose**—Chemotherapy-induced peripheral neuropathy (CIPN) is increasing with introduction of new and combination cancer pharmacotherapies. This study evaluated associations between clinical and self-report measurements and current perception threshold (CPT), a neuroselective measure of sensory nerve function that may detect asymptomatic CIPN damage.

**Methods**—Data for this secondary analysis were from a prospective, observational study using CPT to evaluate CIPN. Bivariate mixed models, accounting for the intra-class correlation between repeated patient assessments, were used to assess the relationship between CPT at each frequency (5Hz, 250Hz and 2000 Hz) and each subjective measure (Neuropathic Pain Scale, FACT-GOGntx) and objective measurement (quantitative sensory testing, deep tendon reflexes, grip strength).

**Results**—A total of 29 chemotherapy-naïve subjects with various cancer types had a mean age of 56.7 (SD 10.4); 9 subjects developed CIPN grade > 1 using NCI CTC-AE criteria. Cold detection thresholds were inversely associated with CPT 5 [b(95% CI) = -2.5(-4.5, -0.5)] and CPT 2000 [-7.5(-11.8, -3.3)] frequencies. FACT GOG-ntx quality of life (QoL) scale and neurotoxicity and function subscales were inversely associated with CPT 2000 [-1.8 (-3.5, -0.05), -2.2 (-4.2, -0.2), and -5.4(-9.8, -0.9), respectively], indicating worsening QoL, impairment, and function as hypoesthesia increases.

**Conclusions**—CPT 2000 may identify impending worsening of patient-reported outcomes, such as QoL.

## Keywords

Chemotherapy-induced peripheral neuropathy; CIPN; chemotherapy; quality of life; pain; cancer

## INTRODUCTION

The number of patients affected with chemotherapy-induced peripheral neuropathy (CIPN) is anticipated to increase proportionately as clinical trials using new neurotoxic agents increase, dosing of existing agents intensifies, and long-term survival improves [1, 2]. Combination chemotherapy involving more than one neurotoxic agent coupled with higher

cumulative doses of these drugs hasten CIPN development[3, 4]. CIPN may involve sensory, motor, and autonomic nerves, which result in neuropathic symptoms [5] as well as decline in physical function and quality of life. Initial symptoms of CIPN commonly include numbness, tingling, and burning pain in a stocking-and-glove distribution.

A number of chemotherapy agents have been implicated in the development of CIPN, including taxanes and platinum agents, two drug classes routinely given in commonly diagnosed malignancies [6]. The CIPN associated with these drugs is dose dependent, with an incidence of up to 100% reported with some high dose regimens [7, 8]. Taxanes, which include paclitaxel and docetaxel, cause a length-dependent axonal polyneuropathy with a distal predominance. In animal experiments with paclitaxel, abnormal pain responses, including allodynia and hyperalgesia to thermal and mechanical stimuli, were sensitive to measures of neuropathic pain [9], suggesting impairment of function in A $\beta$  and A $\delta$  myelinated fibers [10]. Among platinum agents, which include cisplatin, carboplatin, and oxaliplatin, cisplatin has been shown to reduce fast axonal transport and to induce apoptosis in dorsal root ganglion cells, two mechanisms thought to be at least in part responsible for neuropathy symptoms [11]. Large, myelinated A $\beta$  fibers are most commonly affected by this class of drugs. Patients treated with oxaliplatin develop a protracted and sometimes severe CIPN course, which include acute symptoms that resolve within about week, as well as chronic symptoms, characterized by distal paresthesias with numbness [12].

Measures of CIPN used in oncology clinics typically encompass sensory, motor, and functional components, the latter of which is often referred to as quality of life (QoL). Commonly used measures of CIPN in clinical trials include National Cancer Institute Common Terminology Criteria (NCI-CTCAE) v3.0 [13], Eastern Cooperative Group [14], and World Health Organization [15] criteria. These scales range from 0 (asymptomatic) to 4 or 5 (paralysis or death), and as such their ordinal construct limits the scale's ability to detect incremental changes in impairment [16]. As a consequence of inadequate CIPN measurement and lack of standardization, the progression and resolution of CIPN are not well characterized, and sensory nerve fiber damage can become irreversible by the time CIPN is identified clinically [17].

Current perception threshold (CPT) testing uses a painless electrical impulse to stimulate and measure sensory nerve functional integrity by determining the amount of current needed to stimulate a sensation that can be perceived by the subject [18–20]. The CPT test is neuroselective for each of the three major sub-populations of sensory nerve fibers[21], and a unique and distinct sensory response is evoked from each CPT frequency, corresponding to the particular sensory fiber subtype. The frequency required to depolarize and cause an action potential in a nerve is dependent on the diameter of the fiber [22]. The large myelinated A $\beta$  fibers are stimulated at 2000 Hz, the small myelinated A $\delta$  fibers are stimulated at 250 Hz, and the small unmyelinated C fibers are stimulated at 5 Hz. Reduced CPT findings indicate a hyperesthetic condition (less current is needed to evoke a response) seen early in CIPN. Elevated CPT results indicate a loss of nerve function (more current is needed to evoke a response), reflecting a hypoesthesia, which is typical after repeated insults with neurotoxic chemotherapy.

Normative values for CPT have been established in healthy populations in both the United States (Neurotron.com) and abroad [23]. CPT testing has been validated and well-documented in peripheral neuropathy resulting from several different etiologies [24–27]. CPT values were found to decrease in diabetic patients at the 2000 Hz frequency, and these values were moderately correlated with vibration testing [28]. However, studies utilizing CPT testing for evaluation of CIPN in cancer patients are limited. In patients with ovarian cancer treated with paclitaxel and carboplatin, CPT values peaked within days of

chemotherapy administration, indicating hyposensitivity or sensory dullness. The CPT changes were seen at 2000Hz, corresponding to large, A $\beta$  myelinated nerve fibers, which are associated with touch, mild pressure, and vibration. Over time, CPT values decreased as patient complaints of CIPN rose, consistent with hyperesthesia[29].

When neurons become hyperexcitable, the amount of stimulation required to instigate depolarization and action potential is lowered. This in turn may result in a significant decrease in the CPT. If CPT is adequately sensitive and reliable in detecting sensory function changes at an early point during chemotherapy, the potential exists for improvement of clinical care and CIPN management. The primary purpose of this pilot study was to evaluate feasibility of the CPT for use in an oncology population. In addition, we sought to investigate associations between CPT and clinical measures of CIPN, including quantitative sensory testing (QST), deep tendon reflexes, strength, and self-reported symptoms in patients receiving taxane and platinum chemotherapy in order to begin to understand.

## METHODS

### Data Collection

Data from a prospective, observational pilot study, designed to evaluate the development of CIPN using CPT, were abstracted into a data file for this analysis using SAS version 9.0. The clinical study consisted of a convenience sample of 35 adult subjects at the University of Maryland Greenebaum Cancer Center.

Study eligibility included a) age 21 – 85 years; b) diagnosis with a solid tumor; c) planned receipt of taxane and/or a platinum compound; d) chemotherapy-naïve; and e) able to speak English and provide written informed consent. Patients were excluded if they had a life expectancy of less than 3 months or neuropathy from pre-existing conditions. Chemotherapy was administered under direction of the treating physician at Greenebaum Cancer Center. All subjects who developed neuropathy were managed with standard supportive care.

Following approval by the University of Maryland Institutional Review Board, informed consent was obtained followed by collection of demographic and cancer treatment information. At baseline and with each drug cycle, which typically occurred every 7, 21, or 28 days, CIPN measurements were done. For participants who ended chemotherapy prematurely due to CIPN, a final set of study measurements was done at the last study visit. All other participants had ongoing assessments and underwent a final end of study assessment either at completion of the chemotherapy regimen, or following 6 months of treatment, whichever came first.

CIPN was graded using the NCI-CTCAE v3.0 for sensory neuropathy. The diagnosis of CIPN was based on the NCI-CTCAE v3.0 grade of 1 for sensory neuropathy, with at least a report of paresthesias of fingers or toes (grade 1). CIPN grading ranges from 1, which is a mild neuropathy not interfering with function, to 5, which is death. Participants without evidence of CIPN were classified as “no neuropathy.”

### Measures

Sensory function assessments were made using CPT, quantitative sensory testing (QST), and mechanical sensation at the right great toe. Rationale for QST was to assist in determining sensory loss (hypoesthesia, hypoalgesia) or sensory gain (hyperesthesia, hyperalgesia, allodynia) during the course of the patient’s chemotherapy. In addition, motor function was evaluated by measuring grip strength of the dominant hand and deep tendon reflexes at the ankle of the right leg. Subjective questionnaires included the Neuropathic Pain Scale (NPS)

and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT&GOG $_{ntx}$ ).

Patient-reported subjective assessments were obtained prior to objective testing, to avoid potential influence of examinations on patient subjective responses and recall of symptoms. CPT measures were collected prior to other objective measures to avoid any influence of other clinical examinations on CPT measures. QST measures were sequenced consistent with the standardized QST protocol developed by Rolke [30], which orders frequency testing from smaller A $\delta$  and C-fibers to larger A $\beta$  sensory fiber function (table 1).

### Subjective Measures

**National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE):** This study utilized the neuropathy symptom profile of NCI-CTCAE v3.0, which includes sensory, motor, and pain symptoms [13]. Five categories of severity are graded from 1 (asymptomatic) to 5 (deceased). NCI-CTCAE v3.0 demonstrates moderate inter-rater reliability (ICC=0.71–0.75) for the sensory item [31]. Grade 1 or higher was used to classify subjects as having CIPN in this study, and only the sensory neuropathy item was used to classify patients.

**Neuropathic Pain Scale:** The Neuropathic Pain Scale (NPS) is a 10-item multidimensional tool that includes self-report visual analogue scales to quantify two global pain domains (pain intensity and unpleasantness), six neuropathic pain qualities (sharp, dull, hot, cold, sensitive, itchy), two pain locations (surface and deep), and one semi-structured question about temporal sequence [32]. The measure has been validated in patients with a number of diseases. The majority of the 10 items demonstrated correlations  $r < 0.50$  with one another, supporting item discriminant validity [32]. A higher score is associated with increased pain.

**FACT&GOG-  $N_{tx}$ :** This 38-item chemotherapy treatment effect specific measurement tool used to evaluate the severity and impact of CIPN symptoms on functional status and health-related quality of life [33]. For the FACT&GOG-  $N_{tx}$ , higher scores indicate better quality of life. The FACT&GOG-  $N_{tx}$  has demonstrated reliability, with a Cronbach's alpha of 0.81 for the neurotoxicity subscale and an overall Cronbach's alpha of 0.84. Furthermore, the FACT&GOG- $N_{tx}$  and the  $N_{tx}$  subscale have demonstrated sensitivity to clinical change over time [33]. The FACT&GOG-  $N_{tx}$  overall score with its neurotoxicity subscale ( $ntx$ ) was able to differentiate between the chemotherapy naive and those with CIPN ( $p < 0.01$ ), indicating discriminant validity. Others reported the area under the curve for receiver operating curve FACT&GOG- $N_{tx}$  as 0.81, indicating a good ability of the measure to discriminate between patients with and without an NCI- CTC-documented CIPN [34]. A functional subscale of the FACT&GOG- $N_{tx}$ , the Trial Outcome Index (TOI), was also used in this analysis to evaluate aspects of physical function. The TOI is calculated by adding scores from physical well-being, functional well-being, and CIPN symptoms subscales.

### Objective Measures

**Current Perception Threshold (CPT):** The Neurometer® (Neurotron, Baltimore MD) uses a painless electrical stimulus, which generates constant alternating current via sinusoid waveform with a stimulus output intensity range of 0.01 to 9.99 milliamperes (mA). The skin of the stimulus site is cleaned with a mildly abrasive cream to remove any excess oil or dead skin that could impede the transmission of the electrical stimulus. The introduction of electrical stimulation is through two gold electrodes (12mm diameter) placed on the surface of the skin resulting in distal afferent sensory nerve fiber depolarization, which is transmitted and perceived by the individual being tested. As previously described, lower

CPT values indicate hyperesthesia, with higher values consistent with hypoesthesia, which is indicative of established CIPN.

**Quantitative Sensory Testing (QST):** QST measurements were assessed at the right great toe, targeting the peroneal nerve using the following order described in Table 1. Thermal sensation was assessed by measuring warm and cold detection threshold (WDT & CDT), the number of paradoxical heat sensations with alternating cold and warm stimuli or thermal sensory, and cold and heat pain threshold. Mechanical sensation was measured by determining mechanical detection threshold, pinprick detection, and vibration perception threshold. In addition to the QST measures, two tests of sensorimotor function (grip strength, deep tendon reflexes) were included to assess the effects of the neurotoxic drugs on the sensorimotor system.

**Thermal detection thresholds:** Thermal testing was measured using the Pathway Model ATS (Medoc, Israel) peltier device. This device is computer operated, and study subjects were provided with a button to terminate the stimulus at any time during the testing procedure. A thermode with a 16 x16 mm surface area was applied to the plantar surface of the right great toe, and a baseline thermode temperature was set to 32°C. During application of the thermal stimuli, the temperature increased or decreased from 32°C with a 1°C/s ramp and the stimuli were terminated when the subject first perceived the hot or cold sensation and pressed the stop button. Mean detection threshold temperatures were calculated from three consecutive cold and three consecutive warm measurements. During threshold detection testing, the subjects were asked to report any paradoxical heat sensations, which were recorded by the investigator. C fibers are tested using this instrument. For warm detection threshold, reduced heat tolerance is associated with CIPN. Similarly, with cold detection threshold, reduced cold tolerance is associated with CIPN.

**Mechanical detection thresholds:** MDT was obtained using Semmes Weinstein monofilaments (Touch Test Sensory Kit, myNeuroLab.com), beginning with the 2.83 fiber (.07 g). During testing, the fiber was applied perpendicular to the plantar surface of the great toe until the fiber began to bend and was held in place for 1 second and removed. This was repeated 3 times and the subject was asked to report the ability to feel the fiber when it was applied. If the subject was able to detect the application of this fiber in at least 1 out of 3 applications, the testing stopped and this fiber was recorded as the mechanical detection threshold [35]. If the application was not detected, the subject was tested with the next larger fiber in the series. The reliability of mechanical detection threshold using Semmes-Weinstein monofilament fibers (SWMF) has been established in healthy participants and in patients with neuropathic injury [36,37]. Aβ fibers are tested using this method. Greater gram force is required for a positive test in patients with CIPN.

**Vibration perception threshold (VPT):** Vibration detection was measured using a graduated tuning fork (Rydel-Seiffer, US Neurologicals, Poulsbo, Washington) placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated weights at the ends, and as the amplitude decreases, the intersection of the triangles moves upward on the weight (toward the 8 mark). This test was performed three times and a mean of the scores calculated. The reliability and validity for use of the Rydel-Seiffer graduated tuning fork has been reported in several reports in healthy subjects and in those with various peripheral neuropathic pathology [38–40]. Aβ fibers are tested using this method. Vibration sensation is lost sooner in CIPN, which means that lower scores are associated with increased CIPN.

**Pinprick sensibility:** Pinprick detection was assessed using a sterile 18g needle (sharp stimulus) and a sterile paper clip with one end bent at 90° away from the clip body to form a probe (dull stimulus). Three sharp and three dull stimuli (total of 6) were applied in a random order to the plantar surface of the right great toe with sufficient force to cause a slight indentation but no puncture of the skin. With each application, the subject was asked to identify whether the sensation was sharp or dull. The investigator recorded the stimulus type and subject response. The reproducibility of pinprick sensation between examiners is fair in patients with diabetes (Cohen's  $\kappa=0.36$ ) [41]. When compared to healthy controls, subjects with CIPN demonstrated significant reductions in pin prick sensibility ( $p<.001$ ) [10]. A $\delta$  fibers are evaluated using this test. Lower scores are associated with CIPN.

**Deep Tendon Reflexes:** Deep tendon reflexes were tested at the ankle of the right leg. With foot supported, a reflex hammer was used to strike the Achilles tendon. This test was performed three times, and a mean of the scores was calculated. Reflexes were graded on a 0 – 4+ plus scale using the National Institute of Neurological Disorders and Stroke (NINDS) guidelines [42]. When combined with vibration perception and position sensibility, these measures identify peripheral neuropathy in older diabetics with a sensitivity of 94% and specificity of 84% [43]. Lower scores indicate reduced DTRs, which are seen in CIPN.

**Grip Strength:** Grip strength of the dominant hand was measured using a Jamar Dynamometer (US Neurologicals, Poulsbo, Washington). The subject was then asked to quickly exert a maximal grip force and then relax the grip. The investigator recorded the maximal force and reset the dynamometer needle to zero. This test was performed three times, with a rest period of 30 seconds between trials, and a mean of the scores was calculated. Lower scores are associated with decreased motor strength.

### Statistical Analysis

Descriptive analyses were conducted with mean and standard deviation for continuous variables and proportions for categorical variables. T-tests assessed the differences of continuous variables (age and number of chemotherapy cycle) between the CIPN group and non-CIPN group; Chi-square/Fisher's exact test, whichever was appropriate, tested the difference for categorical variables (race, gender, and patient characteristics) among the two groups. Bivariate mixed models accounting for the intraclass correlation between repeated assessments in patients were used to assess the relationship between CPT at each frequency (5Hz, 250Hz and 2000 Hz) and each of the subjective and objective measurements described in Table 1.

## RESULTS

Following Institutional Review Board approval of the study, 35 patients provided written consent to participate and were enrolled. Of the 35 subjects, 6 were not included in the final analysis due to death prior to the second treatment (n=1), concurrent enrollment in another treatment study which precluded continued participation (n=1), failure to disclose a pre-existing neuropathy (n=1), and transfer of medical care to another facility (n=3). For the final data analysis, therefore, 29 subjects were evaluable. In the present analysis, the sample eligible for analysis included the same 29 subjects from the primary study, based on identical eligibility criteria.

Overall, the mean age of participants was 57 years, and the average number of chemotherapy visits was 7. Descriptive statistics of the participants are provided in Table 2. Independent samples t-test showed no statistically significant differences between the mean age of those developing CIPN versus those who did not develop CIPN ( $p=0.368$ ). Similarly

there were no significant differences between subjects with and without CIPN in regard to gender ( $p=0.245$ ) or race ( $p=0.106$ ). There were, however, differences between groups in the number of chemotherapy cycles, with those developing CIPN having received more treatment ( $p=0.014$ ). According to the NCI-CTCAE v 3.0 definition of CIPN used in this study grade 1), nine participants developed sensory symptoms consistent with CIPN, three of whom progressed in severity sufficient to require chemotherapy cessation. Amongst the final clinical tests, which were conducted in subjects at their highest cumulative chemotherapy dose, warm detection thresholds differed between individuals with and without NCI-CTCAE determined CIPN ( $p=0.01$ ). For self-report measures, the FACT total score ( $p=0.006$ ) as well as the FACT ntx neurotoxicity subscale ( $p<0.001$ ) and NPS ( $p=0.014$ ) were significantly different between those with and without NCI-CTCAE determined CIPN (Table 3). There was no significant relationship between CIPN and CPT at each frequency (2000 Hz,  $p=0.80$ ; 250 Hz,  $p=0.76$ ; 5 Hz,  $p=0.15$ , Table 4).

### Associations between CPT and Clinical Measures

Cold detection thresholds were inversely associated with CPT 5 ( $b=-2.5$ , 95%CI:  $(-4.5, -0.5)$ ) and 2000 frequencies ( $b=-7.5$ , 95%CI:  $(-11.8, -3.3)$ ), indicating reduced ability to tolerate cold temperatures as hyperesthesia increased (Table 5). Deep tendon reflexes were also inversely associated with CPT 2000 ( $b=-52.8$ , 95%CI:  $(-94.6, -10.9)$ ), indicating diminished reflexes in the presence of hypoesthesia. No other associations were found between any CPT frequency and remaining clinical tests. Among subjective measures, the FACT&GOG total score [ $b=-1.8$ ; 95%CI:  $(-3.5, -0.05)$ ] as well as *ntx* neurotoxicity [ $b=-5.4$ , 95%CI:  $(-9.8, -0.9)$ ] and *toi* function subscales [ $b=-2.2$ , 95%CI:  $(-4.2, -0.2)$ ] were inversely associated with CPT 2000, indicating reduced QoL, increased CIPN symptoms, and reduced function as hypoesthesia increases. The NCI-CTCAE V3.0 sensory neuropathy item was positively associated with CPT 2000 [ $b=37.5$ , 95%CI:  $(1.4, 73.6)$ ], demonstrating more CIPN symptoms as hypoesthesia increased

## DISCUSSION

This exploratory pilot study, which included subjects with a variety of malignancies and associated chemotherapy regimens, was designed as a proof-of-concept study to evaluate the feasibility of using CPT in CIPN patients. Participant enrollment and retention in this longitudinal study demonstrated feasibility of using CPT in patients undergoing chemotherapy. CPT 2000 was the frequency most often associated with physical examination and subjective measures of CIPN, suggesting a potential role for CPT 2000 in evaluating patients prior to and along the neurotoxic treatment trajectory. However, with the presumed specificity of CPT 2000 for large, myelinated A $\beta$  fibers, CPT findings are challenged by the correlation observed with cold detection thresholds, reflecting changes in small, unmyelinated nerve fiber conduction and functional thresholds. As expected, in view of the frequent decrease or disappearance of deep tendon reflexes in CIPN patients, an inverse association with CPT 2000 was identified, indicating increased hyporeflexia as hypoesthesia progresses [44].

CPT 2000 was also associated with a well-validated measure of neuropathy-related quality of life, the FACT&GOG overall score, as well as its neurotoxicity and functional subscales. This association suggests an important clinical opportunity, because increased CPT readings may indicate impending reduction in quality of life and serve as a red flag for clinicians as they plan treatment which may further reduce performance of daily activities. The NCI-CTCAE v3.0 sensory score also was associated with CPT 2000 Hz, indicating CIPN impairment occurs commensurate with worsening hypoesthesia, and providing evidence of convergent validity of CPT 2000 in identifying sensory neuropathy. The lack of significant



mean differences between groups with and without CIPN on CPT frequencies is not surprising, given the small sample of individuals with CIPN and wide range of drug type and cumulative dose for the overall sample. Future research in a larger, homogeneous patient population, where an effect can be demonstrated, will provide a more accurate evaluation of how well CPT differentiates patients with and without CIPN.

## Limitations

The small sample size restricted possible analyses, allowing mainly for descriptive statistics and bivariate associations. Furthermore, subject heterogeneity may have precluded additional significant findings. Although patients with a variety of malignancies and chemotherapy regimens provided important early information about ability to recruit subjects as well as the value of CPT in assessing CIPN impairment across treatments, future study involving subjects with the same chemotherapy regimen will reduce potential confounding influences during CPT evaluation. Another benefit of conducting CPT examinations in subjects with identical chemotherapy includes more sophisticated statistical analyses, such as mixed modeling, where inter-correlations between treatments may be controlled for each patient. Measurement consistency may have been affected by multiple examiners. Inter-rater reliability was not examined during the study, and in future studies, evaluating the similarity with which raters are implementing clinical tests will assure that clinical examinations are being conducted consistently enough to reduce concern that individual rater variability is introducing during study implementation. However, these preliminary results indicate that CPT, a non-invasive, objective tool to measure the integrity of selected nerve fibers, deserve to be tested in a large, prospective study in homogeneous series of patients undergoing neurotoxic chemotherapy.

The use of CTCv3.0 criteria for classifying participants with CIPN is not a sensitive or specific measure of the phenomenon. In future studies, it is prudent to employ a more robust clinical measure of CIPN, such as Total Neuropathy Score<sup>®</sup>-clinical version, in order to make more confident classification of presence and degree of CIPN. This will allow for improved interpretation of CPT findings in the setting of CIPN.

CPT 2000 measurement may allow anticipation of impending worsening of patient-reported outcomes, such as QOL, and could be useful for earlier intervention with chemotherapy dose modification, pharmacologic treatment, or other preventive measures as they are developed. In addition, CPT 5 may be a potentially useful evaluation of earlier onset CIPN affecting C fiber activity, especially when used in conjunction with CPT 2000. Longitudinal study is required in larger groups of subjects with more homogeneous chemotherapy regimens in order to provide definitive data about the predictive value of CPT, however. If predictive validity is established in future, identification of changes in sensory fiber function following chemotherapy initiation and prior to symptom onset may lead to earlier CIPN detection when testing novel chemotherapeutic agents. Such strides will improve the likelihood that patients achieve chemotherapy completion while avoiding permanent nerve damage and declines in function as well as QoL.

## Acknowledgments

The authors would like to acknowledge the contributions of Sharon Gordon, DDS, MPH, PhD, University of Maryland, Baltimore School of Dentistry, and Raymond Dionne, DDS, PhD, Food and Drug Administration, for their critical input into study conceptualization and design.

Funding Source:

National Institute of Health/National Institute of Nursing Research research grant, P30 University of Maryland, Baltimore Center for Pain Studies to S.G. Dorsey (NRO11396-01).

*Support Care Cancer.* Author manuscript; available in PMC 2015 May 01.

## References

1. Edwards BK, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. *Journal of the National Cancer Institute*. 2005; 97(19): 1407–1427. [PubMed: 16204691]
2. World Health Organization. International Classification of Functioning, Disability, and health (ICF). 2001.
3. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. *J Clin Oncol*. 2006; 24(10):1633–42. [PubMed: 16575015]
4. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimens. *Eur J Cancer*. 2006; 42(1):24–30. [PubMed: 16293411]
5. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. *Ann Oncol*. 2000; 11(5):509–13. [PubMed: 10907941]
6. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. *J Neurol*. 2002; 249(1):9–17. [PubMed: 11954874]
7. Chaudhry V, et al. Inter- and intraexaminer reliability of nerve conduction measurements in patients with diabetic neuropathy. *Neurology*. 1994; 44(8):1459–62. [PubMed: 8058149]
8. Polomano RC, et al. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. *Pain*. 2001; 94(3):293–304. [PubMed: 11731066]
9. Roytta M, Raine CS. Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ. *J Neurocytol*. 1985; 14(1):157–75. [PubMed: 2861255]
10. Dougherty PM, et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. *Pain*. 2004; 109(1–2):132–42. [PubMed: 15082135]
11. Fischer SJ, et al. Alterations in cell cycle regulation underlie cisplatin induced apoptosis of dorsal root ganglion neurons in vivo. *Neurobiol Dis*. 2001; 8(6):1027–35. [PubMed: 11741398]
12. Andre T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med*. 2004; 350(23):2343–51. [PubMed: 15175436]
13. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol*. 2003; 13(3):176–81. [PubMed: 12903007]
14. Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982; 5(6):649–55. [PubMed: 7165009]
15. Miller AB, et al. Reporting results of cancer treatment. *Cancer*. 1981; 47(1):207–14. [PubMed: 7459811]
16. Cavaletti G, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. *J Peripher Nerv Syst*. 2006; 11(2):135–41. [PubMed: 16787511]
17. Wolf S, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. *Eur J Cancer*. 2008; 44(11):1507–15. [PubMed: 18571399]
18. Ma L, et al. Single application of A2 NTX, a botulinum toxin A2 subunit, prevents chronic pain over long periods in both diabetic and spinal cord injury-induced neuropathic pain models. *J Pharmacol Sci*. 2012; 119(3):282–6. [PubMed: 22785019]
19. Matsumoto M, et al. Characterization of three different sensory fibers by use of neonatal capsaicin treatment, spinal antagonism and a novel electrical stimulation-induced paw flexion test. *Molecular Pain*. 2006; 2:16. [PubMed: 16681855]
20. Matsumoto M, et al. Pharmacological switch in Aβ-fiber stimulation-induced spinal transmission in mice with partial sciatic nerve injury. *Molecular Pain*. 2008; 4:25. [PubMed: 18620588]
21. Koga K, et al. Selective activation of primary afferent fibers evaluated by sine-wave electrical stimulation. *Molecular Pain*. 2005; 1:13. [PubMed: 15813963]
22. Katims JJ, et al. Constant current sine wave transcutaneous nerve stimulation for the evaluation of peripheral neuropathy. *Arch Phys Med Rehabil*. 1987; 68(4):210–3. [PubMed: 3032128]

23. Takekuma K, et al. Age and gender differences in skin sensory threshold assessed by current perception in community dwelling Japanese. *Journal of Epidemiology*. 2000; 10(1):S33–S38. [PubMed: 10835826]
24. Rendell MS, et al. Mapping diabetic sensory neuropathy by current perception threshold testing. *Diabetes Care*. 1989; 12(9):636–40. [PubMed: 2791826]
25. Rendell MS, et al. A comparison of nerve conduction velocities and current perception thresholds as correlates of clinical severity of diabetic sensory neuropathy. *J Neurol Neurosurg Psychiatry*. 1989; 52(4):502–11. [PubMed: 2738593]
26. Masson EA, Boulton AJ. The Neurometer: validation and comparison with conventional tests for diabetic neuropathy. *Diabet Med*. 1991; 8(Spec):S63–6. [PubMed: 1825961]
27. Nishimura H, et al. Weekly paclitaxel therapy for locoregional lymph node recurrence of estrogen-receptor-negative breast cancer. *Gan To Kagaku Ryoho*. 2004; 31(4):627–30. [PubMed: 15114714]
28. Tack CJ, et al. Comparison of clinical examination, current and vibratory perception threshold in diabetic polyneuropathy. *Neth J Med*. 1994; 44(2):41–9. [PubMed: 8208323]
29. Doi D, et al. Evaluation of the neurotoxicity of paclitaxel and carboplatin by current perception threshold in ovarian cancer patients. *J Nihon Med Sch*. 2003; 70(2):129–34.
30. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. *Pain*. 2006; 123(3):231–43. [PubMed: 16697110]
31. Cavaletti G, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. *Ann Oncol*. 2013; 24(2):454–62. [PubMed: 22910842]
32. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. *Neurology*. 1997; 48(2):332–8. [PubMed: 9040716]
33. Calhoun EA, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. *Int J Gynecol Cancer*. 2003; 13(6):741–8. [PubMed: 14675309]
34. Huang HQ, et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. *Int J Gynecol Cancer*. 2007; 17(2):387–93. [PubMed: 17362317]
35. Bell-Krotoski JA, et al. Threshold detection and Semmes-Weinstein monofilaments. *J Hand Ther*. 1995; 8(2):155–62. [PubMed: 7550627]
36. de Sonnaville JJ, et al. The prevalence and determinants of foot ulceration in type II diabetic patients in a primary health care setting. *Diabetes Res Clin Pract*. 1997; 35(2–3):149–56. [PubMed: 9179471]
37. Felix E, Widerstrom E. Reliability and validity of quantitative sensory testing in persons with spinal cord injury and neuropathic pain. *Journal of Rehabilitation Research & Development*. 2009; 46:69–84. [PubMed: 19533521]
38. Hilz MJ, Dutsch M, Neundorfer B. Autonomic disorders in polyneuropathies. *Med Klin (Munich)*. 1998; 93(9):533–40. [PubMed: 9792019]
39. Martina IS, et al. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. *European Inflammatory Neuropathy Cause and Treatment (INCAT) group*. *J Neurol Neurosurg Psychiatry*. 1998; 65(5):743–7. [PubMed: 9810949]
40. Merkies IS, et al. Reliability and responsiveness of a graduated tuning fork in immune mediated polyneuropathies. *The Inflammatory Neuropathy Cause and Treatment (INCAT) Group*. *J Neurol Neurosurg Psychiatry*. 2000; 68(5):669–71. [PubMed: 10766905]
41. Smieja M, et al. Clinical examination for the detection of protective sensation in the feet of diabetic patients. *International Cooperative Group for Clinical Examination Research*. *J Gen Intern Med*. 1999; 14(7):418–24. [PubMed: 10417599]
42. Hallett M. NINDS myotatic reflex scale. *Neurology*. 1993; 43(12):2723. [PubMed: 7802740]
43. Richardson JK. The clinical identification of peripheral neuropathy among older persons. *Arch Phys Med Rehabil*. 2002; 83(11):1553–8. [PubMed: 12422324]

44. Fauci, AS., et al. Harrison's Principles of Internal Medicine. Fauci, AS., et al., editors. Vol. 18e. 2012.

**Table 1**

Description and Sequence of Measures Administered at Each Visit

Test	Test Score Associations with CIPN	Afferent Nerve Fibers Tested
NCI Common Toxicity Criteria	Increased	
Neuropathic Pain Scale	Increased	
FACT&GOG <sub>ntx</sub>	Decreased	
CPT	Increased early (hyperesthesia) Decreased later (hypoesthesia)	C (CPT 5 Hz) A $\delta$ (CPT 250 Hz) A $\beta$ (CPT 2000 Hz)
A. Thermal Detection Thresholds		
1. Cold Detection Threshold	Increased temperature	C
2. Warm Detection Threshold	Decreased temperature	C
B. Pinprick Detection	Decreased frequency	A $\delta$
C. Mechanical Detection Threshold	Increased monofilament gauge	A $\beta$
D. Vibration Detection	Decreased time to extinction	A $\beta$
E. Grip Strength	Decreased strength	none
F. Deep Tendon Reflex	Decreased reflex response	A $\beta$

**Table 2**

## Patient Characteristics

Characteristic	Overall N=29	CIPN N=9	No CIPN N=20
	Mean (SD)		
Age	56.7 (10.4)	54.0 (10.3)	57.9 (10.5)
Number of Chemotherapy cycles	7.0 (3.2)	9.1 (3.3)	6.0 (2.8)
	Frequencies (%)		
Gender			
Male	15 (51.7)	3 (33.3)	12 (60.0)
Female	14 (48.3)	6 (66.7)	8 (40.0)
Race			
Caucasian	17 (58.6)	3 (33.3)	14 (70.0)
African American	10 (34.5)	5 (55.6)	5 (25.0)
Hispanic	1 (3.4)	0	1 (5.0)
Asian	1 (3.4)	1 (11.1)	0
Cancer Site			
Breast	8(27.5)	4 (44.4)	4 (20.0)
Head/Neck	8 (27.5)	2 (22.2)	6 (30.0)
Lung	4 (13.8)	1 (11.1)	3 (15.0)
Gastrointestinal	3 (15.0)	1 (11.1)	3(15.0)
Genitourinary	4 (13.8)	1 (11.1)	3 (15.0)
Skin	1 (3.4)	0	1 (5.0)
Stage of Disease			
I	2 (6.9)	1 (5.0)	1 (11.1)
II	6 (20.7)	5 (25.0)	1 (11.1)
III	11 (37.9)	6 (30.0)	5 (55.6)
IV	10 (34.5)	8 (40.0)	2 (22.2)
Chemotherapy Regimen			
Cisplatin	9 (31.0)	2 (22.2)	7 (35.0)
Paclitaxel	5 (17.2)	4 (44.4)	1 (5.0)
Paclitaxel/Cisplatin	2 (6.8)	0	2 (10.0)
Oxaliplatin	2 (6.8)	1 (11.1)	1 (5.0)
Docetaxel	2 (6.8)	0	2 (10.0)
Carboplatin	1 (3.4)	0	1 (5.0)
Paclitaxel/Carboplatin	5 (17.2)	2 (22.2)	3 (15.0)
Docetaxel/Carboplatin	3 (10.3)	0	3 (15.0)
Chemotherapy Cycle Interval			

Characteristic	Overall N=29	CIPN N=9	No CIPN N=20
Weekly	7 (24.1)	3 (33.3)	4 (5.0)
Every 2 weeks	3 (10.3)	1 (11.1)	2 (10.0)
Every 3 weeks	19 (65.5)	5 (55.6)	14 (70.0)

**Table 3**

Differences of final clinical test scores between those with and without CIPN by t-test

Characteristic	Overall (n=29) Mean(SD)	CIPN status		p-value
		CIPN (n=9) Mean(SD)	No CIPN (n=20) Mean(SD)	
Cold detection threshold	19.1(5.0)	19.8(3.9)	18.7(5.4)	0.576
Warm detection threshold	48.8(3.0)	46.7(4.3)	49.7(1.6)	<b>0.010</b>
Pinprick sensibility	0.78(0.17)	0.78(0.19)	0.78(0.16)	0.961
Vibration detection threshold	5.0(2.4)	4.2(2.9)	5.3(2.2)	0.273
Mechanical detection threshold	1.7(2.2)	2.4(3.4)	1.4(1.5)	0.273
Grip strength	32.4(9.4)	30.1(11.4)	33.5(8.5)	0.385
Ankle deep tendon reflexes	1.1(0.7)	1.0(0.7)	1.2(0.7)	0.482
Neuropathic pain scale	13.3(18.1)	25.2(25.3)	7.9(10.8)	<b>0.014</b>
Fact/GOG-Ntx total score	96.5(19.0)	82.8(14.3)	102.7(17.7)	<b>0.006</b>
FACTntx subscale	9.5(9.6)	21.3(7.9)	4.2(3.7)	<b>&lt;0.001</b>



**Table 4**

Differences in normalized means of final CPT measures between patients with and without CIPN

CPT frequency	CIPN		t (p-value)
	No (N=20)	Yes (N=9)	
CPT2000	626.3 (289.5)	597.4 (277.0)	0.25 (0.80)
CPT250	186.4 (117.1)	172.8 (88.0)	0.31 (0.76)
CPT5	129.2 (124.5)	63.0 (66.9)	1.49 (0.15)

**Table 5**  
 Bivariate association between CPT and clinical measures in linear mixed models using patients as random intercept

Measures	CPT 5			CPT 250			CPT 2000		
	b(95% CI)	p-value	b(95% CI)	p-value	b(95% CI)	p-value	b(95% CI)	p-value	
<b>Clinical Examination</b>									
Measure of C Fiber Activity									
Cold Detection Threshold	<b>-2.5(-4.5, -0.5)</b>	<b>0.015</b>	-2.6(-5.7, 0.4)	0.091	<b>-7.5(-11.8, -3.3)</b>	<.001			
Warm Detection Threshold	2.2(-1.5, 5.9)	0.248	5.2(-0.3, 10.7)	0.066	6.5(-1.1, 14.2)	0.093			
Measure of Aδ Fiber Activity									
Pinprick Sensibility	12.5(-45.4, 70.3)	0.672	-32.8(-119.5, 53.9)	0.457	-50.5(-170.7, 69.7)	0.408			
Measure of Aβ Fiber Activity									
Vibration Detection Threshold	1.3(-4.8, 7.5)	0.675	1.7(-7.6, 10.9)	0.721	-2.8(-16.2, 10.6)	0.684			
Mechanical Detection Threshold	0.9(-5.5, 7.3)	0.778	-2.2(-11.7, 7.4)	0.655	2.0(-11.4, 15.4)	0.771			
Measures of Motor System									
Grip Strength	2.1(-0.1, 4.2)	0.063	1.2(-4.0, 6.4)	0.652	1.2(-4.0, 6.4)	0.652			
Ankle Deep Tendon Reflexes	-16.6(-36.4, 3.2)	0.100	-12.6(-42.5, 17.3)	0.407	<b>-52.8(-94.6, -10.9)</b>	<b>0.014</b>			
<b>Subjective Measures</b>									
Neuropathic Pain Scale	0.4(-0.4, 1.2)	0.301	0.4(-0.7, 1.6)	0.475	0.6(-1.1, 2.3)	0.498			
Fact-GOG-Nix Total Score	-0.02(-0.05, 0.02)	0.346	-0.6(-1.7, 0.6)	0.321	<b>-1.8(-3.5, -0.05)</b>	<b>0.044</b>			
FACT_toi Subscale	-0.4(-1.3, 0.6)	0.454	-0.3(-1.7, 1.1)	0.671	<b>-2.2(-4.2, -0.2)</b>	<b>0.035</b>			
FACT-ntx Subscale	0.2(-1.8, 2.3)	0.822	0.1(-3.0, 3.2)	0.936	<b>-5.4(-9.8, -0.9)</b>	<b>0.019</b>			
NCI-CTCAE v3.0 neuropathy									
Motor item	2.4(-19.9, 24.6)	0.834	-12.9(-46.2, 20.3)	0.443	43.1(-1.8, 87.9)	0.060			
Sensory item	11.8(-5.9, 29.4)	0.191	14.0(-12.6, 40.6)	0.300	<b>37.5(1.4, 73.6)</b>	<b>0.042</b>			
Pain item	2.1(-28.0, 32.3)	0.889	-6.4(-51.6, 38.9)	0.782	1.9(-60.3, 64.0)	0.953			